A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with ...

Semaglutide is linked to a reduced risk for Alzheimer’s disease-related dementia in patients with diabetes vs other antidiabetic drugs, a new study suggests.

Longer-acting glucagon-like peptide-1 (GLP-1) receptor agonists and devices have been recently developed and include once-weekly exenatide, dulaglutide, albiglutide, semaglutide and miniosmotic ...